Alfred Lee, MD, PhD
Professor of Medicine (Hematology)Cards
About
Research
Publications
2025
Utilization Patterns of Hematology Consultation in the Intensive Care Unit: An 11-year Single Center Experience
Allen C, Streiff M, Naik R, Seam N, Kadri S, Lee A, Knauert M, Goshua G. Utilization Patterns of Hematology Consultation in the Intensive Care Unit: An 11-year Single Center Experience. Blood Advances 2025 PMID: 41348859, DOI: 10.1182/bloodadvances.2025018327.Peer-Reviewed Original ResearchMolecular clues to venous thromboembolism recurrence
Ryu J, Lee A. Molecular clues to venous thromboembolism recurrence. Blood 2025, 146: 2281-2282. PMID: 41196621, DOI: 10.1182/blood.2025030460.Peer-Reviewed Original ResearchA proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry
Pine A, Butt A, Andreoli L, Knight J, Gerosa M, Cecchi I, Branch D, Lopez-Pedrera R, Belmont H, Kello N, Petri M, Cervera R, Pengo V, Meroni P, Cohen H, Willis R, Bertolccini M, Goshua G, Gu S, Hwa J, Lee A, Erkan D, Sharda A. A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry. Frontiers In Immunology 2025, 16: 1676578. PMID: 41181143, PMCID: PMC12571811, DOI: 10.3389/fimmu.2025.1676578.Peer-Reviewed Original ResearchConceptsAntiphospholipid syndromeInflammatory signatureClinical trialsAdaptive immune response pathwaysPersistently aPL-positive patientsPathogenesis of antiphospholipid syndromeClinical antiphospholipid syndromePathophysiology of antiphospholipid syndromeAPL-positive patientsCirculating antiphospholipid antibodiesPresence of aPLAntiphospholipid syndrome classificationAdaptive immune activationActivation of coagulationStatistical significanceAntiPhospholipid Syndrome AllianceMultiple pathophysiological mechanismsObstetric morbidityAntiphospholipid antibodiesImmune response pathwaysImmune cellsImmune activationAutoimmune diseasesProteomic screenClinical severityAnalytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome
Butt A, Sharda A, Lee A, Knight J. Analytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome. Transfusion Medicine Reviews 2025, 150909. PMID: 40783311, DOI: 10.1016/j.tmrv.2025.150909.Peer-Reviewed Original ResearchNeutrophil extracellular trapsAntiphospholipid syndromeAdenosine A2A receptorNegative regulatorP-selectin glycoprotein ligand-1Anti-NET antibodiesInduction of NETosisTranscription factor KLF2Regulation of NETosisAutoimmune prothrombotic disorderDecondensed chromatinDevelopment of thrombosisElevated NET levelsNeutrophil-mediated mechanismsGranule proteinsComplement system activationActivated Protein CObstetric complicationsAntiphospholipid antibodiesProthrombotic disordersNeutrophil-derived granule proteinsThrombotic eventsThrombotic riskClinical manifestationsAutoimmune disordersImplementation of a Novel Interdisciplinary Pharmacology Curriculum in a Hematology/Oncology Fellowship Program
Kwaramba T, Forman R, Shamilov R, Goldber S, Lee A, Srikumar T. Implementation of a Novel Interdisciplinary Pharmacology Curriculum in a Hematology/Oncology Fellowship Program. EMJ Oncology 2025, 2: 78-79. DOI: 10.33590/oncolamj/tcyd4672.Peer-Reviewed Original ResearchCalcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Calcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database. Therapeutic Advances In Hematology 2025, 16: 20406207251394775. PMID: 41333634, PMCID: PMC12665816, DOI: 10.1177/20406207251394775.Peer-Reviewed Original ResearchAcquired Aplastic AnemiaCalcineurin inhibitorsTransfusion requirementsTransfusion burdenDouble therapySevere AATriple therapyAplastic anemiaCombination therapyAllogeneic hematopoietic stem cell transplantationEquine anti-thymocyte globulinEffects of calcineurin inhibitorsRare bone marrow failure syndromeHematopoietic stem cell transplantationBone marrow failure syndromesFirst-line treatment optionAnti-thymocyte globulinStem cell transplantationMarrow failure syndromesTreatment-related complicationsImmune-mediated destructionRisk of bleedingRetrospective cohort studyAdherence to treatmentTransfusion-independentInternational Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings.
Roy A, Bakouny Z, Dizman N, Paul M, Ozay Z, Lal B, Nawfal R, Eid M, Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Xie W, Lee A, Choueiri T. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings. JCO Oncology Practice 2025, op2500067. PMID: 40577682, DOI: 10.1200/op-25-00067.Peer-Reviewed Original ResearchInternational medical graduatesAmerican medical graduatesASCO Annual MeetingFaculty rolesMedical graduatesInternational oncology meetingsMultivariate analysis assessed factorsOncology workforceOncology meetingsUnited StatesUnder-recognitionInvited facultyPracticing oncologistsFellowship traineesASCOConference meetingsOriginal researchPresentationMeetingAnnual MeetingPresent dataFacultyGraduatesAcademic rankWorkforceImplementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program.
Forman R, Kwaramba T, Shamilov R, Goldberg S, Lee A, Srikumar T. Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2025, 43: 9028-9028. DOI: 10.1200/jco.2025.43.16_suppl.9028.Peer-Reviewed Original ResearchMechanism of actionCase-basedFellowship programsCancer-directed therapyDrug mechanism of actionTreatment decision makingDosing considerationsPharmacology curriculumToxicity managementTreatment optionsPatient counselingInterdisciplinary patient careLearning science principlesCancer therapeuticsPre-post designCase-based formatPost-lecture surveysThematic qualitative analysisActive learningDrug mechanismsCase-based approachDisease typePost-survey respondentsCase-based curriculumCareer transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis.
Xing J, Wang Q, Tang Y, Lu C, Chen F, Roy A, Deng L, Neupane K, Ardeshir Larijani F, Bekaii-Saab T, Aggarwal C, Lee A, Owonikoko T, Chavez Mac Gregor M, Bakouny Z, Gandhi S, Dizman N, Choueiri T, Perimbeti S, Jiang C. Career transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis. Journal Of Clinical Oncology 2025, 43: 9009-9009. DOI: 10.1200/jco.2025.43.16_suppl.9009.Peer-Reviewed Original ResearchInternational medical graduatesRural-Urban Continuum CodesCancer care deliveryOncology workforceMedical graduatesCare deliveryMedical oncologistsUS graduatesNCI-designated Cancer CentersDesignated cancer centersCross-sectional studyNon-metropolitan areasContinuum CodesWorkforce disparitiesUnderserved regionsSystemic barriersCareer stagesChi-square testPrimary specialtyPracticing medical oncologistsNCI centersStratified analysisAcademic affiliationPractice patternsPrimary outcomeBoard certification practices of US hematologists and oncologists.
Wesevich A, Schmitt L, Wesevich M, Lee A. Board certification practices of US hematologists and oncologists. Journal Of Clinical Oncology 2025, 43: 9034-9034. DOI: 10.1200/jco.2025.43.16_suppl.9034.Peer-Reviewed Original ResearchCenters for Medicare & Medicaid ServicesAmerican Board of Internal MedicineMaintenance of CertificationTeaching hospitalCareer pathwaysRural-Urban Commuting Area codesCertification practicesFemale genderMedical school graduatesSchool graduatesNon-teaching hospitalsMedicare Part BPhysician characteristicsArea codeMedicaid ServicesTrained physiciansNon-metropolitanInternal medicineOpen PaymentsCredentialing practicesMedical schoolsOncology boardUnited StatesFellowship programsMedical oncologists
Academic Achievements & Community Involvement
Clinical Care
Overview
Alfred Ian Lee, MD, PhD, is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education.
He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.
Clinical Specialties
Fact Sheets
Hereditary Hemorrhagic Telangiectasia (HHT)
Learn More on Yale MedicineBleeding Disorders
Learn More on Yale MedicineHodgkin's Lymphoma
Learn More on Yale MedicineAnemia
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- December 09, 2025
Yale research advances presented at American Society of Hematology annual meeting
- December 01, 2025
Yale Cancer Center Experts to Present Latest Findings at American Society of Hematology’s Annual Meeting
- February 06, 2025Source: Medscape
Compassion Fatigue: How Oncologists Can Recognize the Signs
- June 12, 2024
Yale Medical Oncology-Hematology Fellowship Graduation 2024
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Alfred Lee, MD, PhD